Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 313, Issue 2, 2017, Pages H224-H236

  Takawale, Abhijit ^a   Zhang, Pu ^a   Azad, Abul ^a   Wang, Wang ^a   Wang, Xiuhua ^a   Murray, Allan G ^a   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Remodeling; Tissue inhibitor of metalloproteinases 3

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE; TIMP3 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE TRANSFER; HEART DILATATION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE DILATION; HEART LEFT VENTRICLE FAILURE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARDIAC MUSCLE; CELL PROLIFERATION; CONVALESCENCE; CORONARY BLOOD VESSEL; DISEASE MODEL; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; SIGNAL TRANSDUCTION; TIME FACTOR; UPREGULATION;

ADENOVIRIDAE; ANIMALS; CELL PROLIFERATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASES; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOLYSIS; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSDUCTION, GENETIC; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85026758512     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00108.2017     Document Type: Article

References (44)

1. Casagrande V, Menghini R, Menini S, Marino A, Marchetti V, Cavalera M, Fabrizi M, Hribal ML, Pugliese G, Gentileschi P, Schil-laci O, Porzio O, Lauro D, Sbraccia P, Lauro R, Federici M. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 32: 74–81, 2012. doi:10.1161/ATVBAHA. 111.238402.
2. Eckhouse SR, Purcell BP, McGarvey JR, Lobb D, Logdon CB, Doviak H, O’Neill JW, Shuman JA, Novack CP, Zellars KN, Pettaway S, Black RA, Khakoo A, Lee T, Mukherjee R, Gorman JH, Gorman RC, Burdick JA, Spinale FG. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med 6: 223ra21, 2014. doi:10.1126/scitranslmed.3007244.
3. Fan D, Takawale A, Basu R, Patel V, Lee J, Kandalam V, Wang X, Oudit GY, Kassiri Z. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc Res 103: 268–280, 2014. doi:10.1093/cvr/cvu072.
4. Fan D, Takawale A, Shen M, Samokhvalov V, Basu R, Patel V, Wang X, Fernandez-Patron C, Seubert JM, Oudit GY, Kassiri Z. A disintegrin and metalloprotease-17 regulates pressure overload-induced myocardial hypertrophy and dysfunction through proteolytic processing of integrin β1. Hypertension 68: 937–948, 2016. doi:10.1161/HYPERTENSIONAHA.116.07566.
5. Fan D, Takawale A, Shen M, Wang W, Wang X, Basu R, Oudit GY, Kassiri Z. Cardiomyocyte A disintegrin and metalloproteinase 17 (ADAM17) is essential in post-myocardial infarction repair by regulating angiogenesis. Circ Heart Fail 8: 970–979, 2015. doi:10.1161/CIRCHEARTFAILURE.114.002029.
6. Farhan MA, Carmine-Simmen K, Lewis JD, Moore RB, Murray AG. Endothelial cell mTOR complex-2 regulates sprouting angiogenesis. PLoS One 10: e0135245, 2015. doi:10.1371/journal.pone.0135245.
7. Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li RK, Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110: 2401–2409, 2004. doi:10.1161/01.CIR.0000134959.83967.2D.
8. Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother 35: 502–512, 2012. doi:10.1097/CJI. 0b013e3182619c8e.
9. Haddad G, Zhabyeyev P, Farhan M, Zhu LF, Kassiri Z, Rayner DC, Vanhaesebroeck B, Oudit GY, Murray AG. Phosphoinositide 3-kinase β mediates microvascular endothelial repair of thrombotic microangiopathy. Blood 124: 2142–2149, 2014. doi:10.1182/blood-2014-02-557975.
10. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123: 933–944, 2011. doi:10.1161/CIR.0b013e31820a55f5.
11. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104: 2673–2678, 2001. doi:10.1161/hc4601.099485.
12. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 48: 15–20, 2006. doi:10.1016/j.jacc.2006.02.055.
13. Ikonomidis JS, Hendrick JW, Parkhurst AM, Herron AR, Escobar PG, Dowdy KB, Stroud RE, Hapke E, Zile MR, Spinale FG. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: Effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 288: H149–H158, 2005. doi:10.1152/ajpheart.00370.2004.
14. Iyer RP, de Castro Brás LE, Cannon PL, Ma Y, DeLeon-Pennell KY, Jung M, Flynn ER, Henry JB, Bratton DR, White JA, Fulton LK, Grady AW, Lindsey ML. Defining the sham environment for post-myocardial infarction studies in mice. Am J Physiol Heart Circ Physiol 311: H822–H836, 2016. doi:10.1152/ajpheart.00067.2016.
15. Iyer RP, de Castro Brás LE, Jin YF, Lindsey ML. Translating Koch’s postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res 114: 860–871, 2014. doi:10.1161/CIRCRESAHA.114.301673.
16. Johnson TD, Christman KL. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv 10: 59–72, 2013. doi:10.1517/17425247.2013.739156.
17. Kameda K, Matsunaga T, Abe N, Fujiwara T, Hanada H, Fukui K, Fukuda I, Osanai T, Okumura K. Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture. Circ J 70: 673–678, 2006. doi:10.1253/circj.70.673.
18. Kandalam V, Basu R, Abraham T, Wang X, Awad A, Wang W, Lopaschuk GD, Maeda N, Oudit GY, Kassiri Z. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol 299: H1012–H1023, 2010. doi:10.1152/ajpheart.00246.2010.
19. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 106: 796–808, 2010. doi:10.1161/CIRCRESAHA.109.209189.
20. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 124: 2094– 2105, 2011. doi:10.1161/CIRCULATIONAHA.111.030338.
21. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancel-lotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16: 233–270, 2015. doi:10.1093/ehjci/jev014.
22. Lavine KJ, Kovacs A, Weinheimer C, Mann DL. Repetitive myocardial ischemia promotes coronary growth in the adult mammalian heart. J Am Heart Assoc 2: e000343, 2013. doi:10.1161/JAHA.113.000343.
23. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98: 1728–1734, 1998. doi:10.1161/01.CIR.98.17.1728.
24. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 288: H461–H468, 2005. doi:10.1152/ajpheart.00402.2004.
25. Lucitti JL, Mackey JK, Morrison JC, Haigh JJ, Adams RH, Faber JE. Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 and 17. Circ Res 111: 1539–1550, 2012. doi:10.1161/CIRCRESAHA.112.279109.
26. Møller JE, Hillis GS, Oh JK, Reeder GS, Gersh BJ, Pellikka PA. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J 151: 419–425, 2006. doi:10.1016/j.ahj.2005.03.042.
27. Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 17: 693–706, 2012. doi:10.1007/s10741-011-9266-y.
28. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cush-man M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131: e29–e322, 2015. doi:10.1161/CIR.0000000000000152.
29. Patel VB, Wang Z, Fan D, Zhabyeyev P, Basu R, Das SK, Wang W, Desaulniers J, Holland SM, Kassiri Z, Oudit GY. Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments. Circ Res 112: 1542–1556, 2013. doi:10.1161/CIRCRESAHA.111.300299.
30. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407–415, 2003. doi:10.1038/nm846.
31. Roger VL. Epidemiology of heart failure. Circ Res 113: 646–659, 2013. doi:10.1161/CIRCRESAHA.113.300268.
32. Spinale FG, Villarreal F. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol 90: 7–15, 2014. doi:10.1016/j.bcp.2014.04.011.
33. Starr AE, Dufour A, Maier J, Overall CM. Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16. J Biol Chem 287: 5848–5860, 2012. doi:10.1074/jbc.M111.314609.
34. Stöhr H, Roomp K, Felbor U, Weber BH. Genomic organization of the human tissue inhibitor of metalloproteinases-3 (TIMP3). Genome Res 5: 483–487, 1995. doi:10.1101/gr.5.5.483.
35. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948–954, 2000. doi:10.1161/01.CIR.101.9.948.
36. Takawale A, Fan D, Basu R, Shen M, Parajuli N, Wang W, Wang X, Oudit GY, Kassiri Z. Myocardial recovery from ischemia-reperfusion is compromised in the absence of tissue inhibitor of metalloproteinase 4. Circ Heart Fail 7: 652–662, 2014. doi:10.1161/CIRCHEARTFAILURE.114.001113.
37. Takawale A, Sakamuri SS, Kassiri Z. Extracellular matrix communication and turnover in cardiac physiology and pathology. Compr Physiol 5: 687–719, 2015. doi:10.1002/cphy.c140045.
38. Tian H, Cimini M, Fedak PW, Altamentova S, Fazel S, Huang ML, Weisel RD, Li RK. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol 43: 733–743, 2007. doi:10.1016/j.yjmcc.2007.09.003.
39. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: ‘Embracing the MMP-independent-side of the family’. J Mol Cell Cardiol 48: 445– 453, 2010. doi:10.1016/j.yjmcc.2009.09.013.
40. Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, Penninger JM, Kassiri Z, Vederas JC, Murray AG, Oudit GY. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc 2: e000249, 2013. doi:10.1161/JAHA.113.000249.
41. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114: 1020–1027, 2006. doi:10.1161/CIRCULATIONAHA.105.600353.
42. Zavadzkas JA, Stroud RE, Bouges S, Mukherjee R, Jones JR, Patel RK, McDermott PJ, Spinale FG. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res 114: 1435–1445, 2014. doi:10.1161/CIRCRESAHA.114.303634.
43. Zhang QX, Nakhaei-Nejad M, Haddad G, Wang X, Loutzenhiser R, Murray AG. Glomerular endothelial PI3 kinase-α couples to VEGFR2, but is not required for eNOS activation. Am J Physiol Renal Physiol 301: F1242–F1250, 2011. doi:10.1152/ajprenal.00662.2010.
44. Zhang Y, Takagawa J, Sievers RE, Khan MF, Viswanathan MN, Springer ML, Foster E, Yeghiazarians Y. Validation of the wall motion score and myocardial performance indexes as novel techniques to assess cardiac function in mice after myocardial infarction. Am J Physiol Heart Circ Physiol 292: H1187–H1192, 2007. doi:10.1152/ajpheart.00895.2006.